drugset / Trial / NCT01638026

Final Oocyte Maturation Via Administration of GnRH Agonists Followed By Luteal Support With hCG

NCT01638026

Phase 4 Completed 93 enrolled HaEmek Medical Center, Israel
NaSingle-groupOpen-labelTreatment

Summary

Study Objectives: 1. To prove that the use of GnHR agonist for final oocyte maturation results in a higher percentage of mature oocytes than the use of hCG. 2. To show an advantage in women's satisfaction in the proposed protocol versus the standard antagonist protocol In the study group women will receive GnRH agonist for oocyte maturation, followed by ovum pick-up which will be performed 35 hours later. Embryo transfer will be performed 48-72 hours after ovum pick-up. Luteal support will include HCG 1500 IU. Blood samples for BHCG, progesterone and estradiol will be obtained 14 days after embryo transfer.

Timeline

Start
2012-09
Primary completion
2017-07
Completion
2017-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Triptorelin Other / unclassified 0.2 mg
Subject hCG Unknown 1500 iu

Indications